The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies...
Main Authors: | Gwang Sil Kim, Joong Hyun Park, Jong Chul Won |
---|---|
Format: | Article |
Language: | English |
Published: |
Academya Publishing Co.
2019-05-01
|
Series: | Endocrinology and Metabolism |
Subjects: | |
Online Access: | https://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-34-106.pdf |
Similar Items
-
Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
by: Hirotaka Watada
Published: (2020-01-01) -
Mechanistic studies of sodium-glucose cotransporter-2/dipeptidyl peptidase-iv blockade and niacin on pancreatic islet function and glucose homeostasis.
Published: (2013) -
Mechanisms and clinical significance of nephroprotective action of sodium-glucose cotransporter 2 inhibitors
by: I. Y. Pchelin, et al.
Published: (2019-01-01) -
Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure
by: Buse, J., et al.
Published: (2022) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)